Infinity Bio
BALTIMORE, MD · Biotechnology · 25 employees
Infinity Bio is a technology company that provides detailed insights into the immune system using its proprietary antibody profiling platform. The company’s core technology comprehensively measures the antibody reactome, revealing the targets of individual immune responses against all known human viruses, human proteins (autoimmunity), and allergen proteins. Infinity's assay, MIPSA, was developed
Funding history
- Funding Round — $5.0M — Aug 2025
- Series series a — $8.0M — Jun 2025
- Series seed — $2.0M — Mar 2025
- Series seed — $4.5M — Jun 2024
- Series seed — $4.5M — Jun 2023
Recent signals
- Mar 18, 2026: Infinity Bio Appoints Brian McKelligon as Chief Executive Officer
- Aug 20, 2025: Raised $5.0M
- Jun 18, 2025: Raised $8.0M in Series series a
- Mar 11, 2025: Raised $2.0M in Series seed
- Jun 03, 2024: Raised $4.5M in Series seed
- Jun 26, 2023: Raised $4.5M in Series seed
See plans & pricing → Track Infinity Bio’s funding, hiring, and signals — with verified contacts — on Fundz.